Guild Esports “large sponsorship contract provides significant momentum” says Zeus Capital

Gild Esports Bitstamp partnership
[shareaholic app="share_buttons" id_name="post_below_content"]

Guild Esports plc (LON:GILD) announced a three-year sponsorship deal with Bitstamp, valued at £1.5m per annum. Bitstamp is Guild’s largest sponsorship contract to date and more than replaces the contract with the European fintech company that Guild terminated last October. The milestone contract provides Guild with significant momentum. The company’s pipeline is “strong” and Guild looks forward to announcing further contracts in due course. 

  • Guild Esports announced a global sponsorship deal with Bitstamp, the world’s longest-running crypto exchange with four million customers worldwide. Bitstamp will be Guild’s exclusive Official Cryptocurrency Exchange partner, with marketing rights and prominent exposure across Guild’s team jersey and social and digital content Bitstamp’s logo and brand will also be integrated into Guild’s new flagship London headquarters which is due to open in early 2022. The sponsorship will commence on 29th January 2022.
  • The Bitstamp sponsorship is the company’s largest sponsorship contract to date, valued at £4.5m over three years. The Bitstamp contract successfully replaces the contract with the European fintech company that Guild Esports terminated on 25 October 2021 after not receiving clear timelines for launch nor any payments. Indeed, the BitStamp contract is significantly larger than the original contract with the European fintech company (£3.6m over three years). 
  • Sponsorships – The Bitstamp contract adds to a £3.0m two-year sponsorship contract with Subway and display and peripherals partnerships with Samsung and HyperX, valued at about £0.9m over two years.
  • The large sponsorship contract provides significant momentum to Guild Esports. The company says its pipeline of business opportunities is 
Share on:
Find more news, interviews, share price & company profile here for:

    Gilead Sciences, Inc. (GILD) Stock Analysis: Target Price Reveals 8% Potential Upside for Investors

    Gilead Sciences, Inc. (NASDAQ: GILD), a powerhouse in the healthcare sector, stands as a prominent player within the drug manufacturing industry. With a substantial market capitalization of $148.78 billion, Gilead

    Gilead Sciences, Inc. (GILD): Investor Outlook with a Solid 2.61% Dividend Yield and Strategic Collaborations

    Gilead Sciences, Inc. (NASDAQ: GILD) continues to stand as a formidable player in the biopharmaceutical industry, with a robust market capitalization of $150.06 billion. As a leading name in the

    Gilead Sciences, Inc. (GILD) Stock Analysis: Navigating Potential Upside with Robust Dividends

    Gilead Sciences, Inc. (NASDAQ: GILD), a biopharmaceutical giant known for its innovative treatments in areas of unmet medical need, stands as a compelling consideration for investors in the healthcare sector.

    Gilead Sciences (GILD) Stock Analysis: Evaluating a 7.79% Upside Potential in the Healthcare Sector

    Gilead Sciences, Inc. (NASDAQ: GILD), a leading player in the healthcare sector, has been at the forefront of biopharmaceutical innovation, particularly in areas of unmet medical need such as HIV/AIDS

    Gilead Sciences, Inc. (GILD) Stock Analysis: Assessing an 11.10% Upside Potential

    Gilead Sciences, Inc. (NASDAQ: GILD), a titan in the healthcare sector, continues to capture investor attention with its robust pipeline and strategic collaborations in the biopharmaceutical landscape. The company’s current

    Gilead Sciences, Inc. (GILD) Rating Update: Analysts Project an 11.68% Upside Potential

    Gilead Sciences, Inc. (NASDAQ: GILD), a formidable player in the healthcare sector, continues to draw investor interest with its robust pipeline and strategic collaborations. As one of the leading drug

      Search

      Search